RubrYc Therapeutics
San Ramon, US · Founded 2017 · Delaware corporation · 3 known investors
Rubryc discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies for hard-to-drug targets. The company focuses on therapeutic development for patients with limited treatment options.
Founders & leadership
PC
Paul ConleyNamed on SEC filing
BC
Bill ColstonNamed on SEC filing
JH
Jason HongNamed on SEC filing
IJ
Isaac J. BrightNamed on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$9.5M disclosed across 3 rounds · 2018–2019
▶$2.3MraisedJul 2019 · 10 investors · BiotechnologyRule 506(b)
▶$2.3MraisedJul 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bill ColstonExecutive Officer, Director, Promoter
- Isaac J. BrightExecutive Officer, Director
- Jason HongDirector
- Paul ConleyDirector
- Jean ViretDirector
- Offering amount
- $7.5M
- Amount sold
- $2.3M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$5.3MraisedApr 2018 · 8 investors · BiotechnologyRule 506(b)
▶$5.3MraisedApr 2018 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason HongDirector
- Isaac J. BrightExecutive Officer, Director
- Paul ConleyDirector
- Bill ColstonExecutive Officer, Director, Promoter
- Offering amount
- $8.3M
- Amount sold
- $5.3M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.9MraisedApr 2018 · 1 investors · BiotechnologyRule 506(b)
▶$1.9MraisedApr 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul ConleyDirector
- Bill ColstonExecutive Officer, Director, Promoter
- Jason HongDirector
- Isaac J. BrightExecutive Officer, Director
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does RubrYc Therapeutics do?
- Rubryc discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies for hard-to-drug targets. The company focuses on therapeutic development for patients with limited treatment options.
- Who are RubrYc Therapeutics's investors?
- RubrYc Therapeutics's investors include Third Point Ventures, Paladin Capital Group, Vital Venture Capital.
- How much funding has RubrYc Therapeutics raised?
- RubrYc Therapeutics has disclosed $9.5M raised across 3 rounds.
- Where is RubrYc Therapeutics headquartered?
- RubrYc Therapeutics is headquartered in San Ramon, US.